Supply Chain Archives
02/26/2026
Building Investor Confidence Through an Intentional Supply Chain Strategy
In early investment conversations, scientific innovation used to carry most of the weight. A compelling mechanism of action, a clear unmet need, and solid early data together were enough to advance the discussion and give investors a sense of potential. In today’s funding environment, however, that has shifted. Today, investors quickly move past the science and begin investigating whether a program can operate with the discipline and scalability required to grow.
02/18/2026
Build Standardization Where It Matters Most: Turning Stability into True Consistency
There is a quiet assumption that many early-phase teams make when they transition to cryopreserved starting material... that freezing alone will solve their variability problem. On the surface, it feels true. Cryopreservation stops the clock, stabilizes the cells, and removes the minute-to-minute fragility of fresh material. But the stability that teams expect isn’t guaranteed by freezing itself, it’s created by how the freezing is done. And in practice, this is where programs often get surprised.
01/27/2026
Establish Stability from the Start with Frozen Starting Materials for Cell Therapy Development
For many years, cell therapy programs defaulted to fresh leukapheresis-derived starting material. The assumption was that if you could minimize the time from collection to manufacturing, you would maximize viability. As a result, fresh apheresis became not only a scientific preference but an operational tradition, shaping how clinical teams would schedule donors, how manufacturing suites would allocate capacity, and how programs would structure day-to-day execution. Program leaders treated any deviation from “fresh” as a risk to be justified rather than a choice to be evaluated. But reality keeps getting in the way.
01/27/2026
How Defragmenting the Pre-Clinical Supply Chain De-Risks Downstream Operations
Every stage of the supply chain including cryopreservation, logistics, and BioServices and biostorage, must align to ensure a seamless transition from pre-clinical work into Phase I trials. However, early-stage teams often select multiple vendors who each handle one piece of the process because it feels faster or more cost-effective in the moment. This approach, however, builds fragmented supply chains that introduce gaps as programs scale. And when those gaps surface, teams must devote valuable time and effort simply to get back on track.
12/19/2025
Expert Q&A: Is Standardization the Bottleneck or Breakthrough to Building Scalable and Cost-Effective CGT Programs?
Cell and gene therapy (CGT) companies are under constant pressure to do more while hitting milestones earlier. Demonstrate manufacturability. Ensure regulatory readiness. Design for scalability and patient access. And do all of this with more constrained resources and increasingly aggressive timelines. Building on our recent panel discussion, we gathered extended perspectives from Dr. Don Fink (Dark Horse Consulting Group), Audrey Greenberg (Mayo Venture Partners), Dr. Dominic Clarke (Cryoport Systems), and Kurtis Carlisle (Cabaletta Bio).
12/17/2025
2025 Year in Review: Turning Standards and Resilience into Outcomes
If you work within the advanced therapy ecosystem, you already know the story of 2025 from an industry standpoint, where science continued accelerating while funding and commercialization hinged on whether the supporting systems could keep up. For Cryoport Systems, that reality was a catalyst. This year, we raised the bar yet again and demonstrated how having the right strategic partnership behind your end-to-end supply chain can turn logistics into leverage, can transform compliance into confidence, and can spin scale into speed.
10/15/2025
The Connected Chain: Why Supply Chain Integration Matters in Advanced Therapy Manufacturing
Contract Development and Manufacturing Organizations (CDMOs) are at the heart of the advanced therapy ecosystem, managing complex, high-stakes programs that demand speed and compliance. As therapies move from early development into clinical trials and through to commercialization, every stage of manufacturing, packaging, biostorage, and final drug delivery need to align perfectly for seamless execution. Yet in many cases, these functions are managed by multiple vendors, each operating in isolation. The result is a fragmented supply chain that increases risk while slowing execution due to layers of operational burden.
09/10/2025
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.
08/20/2025
